Stryker Co. (NYSE:SYK) Shares Sold by Private Wealth Partners LLC

Private Wealth Partners LLC lowered its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 32,063 shares of the medical technology company's stock after selling 677 shares during the quarter. Private Wealth Partners LLC's holdings in Stryker were worth $11,544,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Dunhill Financial LLC raised its stake in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after buying an additional 37 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Stryker during the 3rd quarter valued at about $36,000. Activest Wealth Management purchased a new position in shares of Stryker during the 4th quarter valued at about $36,000. Crews Bank & Trust purchased a new position in shares of Stryker during the 4th quarter valued at about $39,000. Finally, Hara Capital LLC purchased a new position in shares of Stryker during the 3rd quarter valued at about $42,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Stock Down 1.0 %

Stryker stock traded down $3.75 during midday trading on Friday, reaching $382.67. The company's stock had a trading volume of 650,429 shares, compared to its average volume of 1,368,135. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market cap of $146.02 billion, a P/E ratio of 49.32, a P/E/G ratio of 2.93 and a beta of 0.96. The business has a 50-day simple moving average of $377.92 and a 200-day simple moving average of $368.21.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the firm earned $3.46 EPS. On average, research analysts expect that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is currently 43.30%.

Analysts Set New Price Targets

SYK has been the subject of a number of recent research reports. The Goldman Sachs Group lifted their price objective on Stryker from $384.00 to $427.00 and gave the company a "neutral" rating in a research note on Thursday, January 30th. BTIG Research lifted their price target on Stryker from $383.00 to $394.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Evercore ISI lifted their price target on Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Barclays lifted their price target on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Finally, Canaccord Genuity Group lifted their price target on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and an average target price of $420.68.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.